Sinclair Pharma (XPAR:SPH) Inventory-to-Revenue : 0.22 (As of Jun. 2018)

View and export this data going back to . Start your Free Trial

What is Sinclair Pharma Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Sinclair Pharma's Average Total Inventories for the quarter that ended in Jun. 2018 was €5.40 Mil. Sinclair Pharma's Revenue for the six months ended in Jun. 2018 was €24.20 Mil. Sinclair Pharma's Inventory-to-Revenue for the quarter that ended in Jun. 2018 was 0.22.

Sinclair Pharma's Inventory-to-Revenue for the quarter that ended in Jun. 2018 increased from Dec. 2017 (0.18) to Dec. 2017 (0.22)

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Sinclair Pharma's Days Inventory for the six months ended in Jun. 2018 was 134.29.

Inventory Turnover measures how fast the company turns over its inventory within a year. Sinclair Pharma's Inventory Turnover for the quarter that ended in Jun. 2018 was 1.36.

Sinclair Pharma Inventory-to-Revenue Historical Data

The historical data trend for Sinclair Pharma's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinclair Pharma Inventory-to-Revenue Chart

Sinclair Pharma Annual Data

Trend

Jun07

Jun08

Jun09

Jun10

Jun11

Jun12

Jun13

Jun14

Jun15

Dec17

Inventory-to-Revenue

Get a 7-Day Free Trial

0.14

0.10

0.26

0.15

Sinclair Pharma Semi-Annual Data
	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Jun17	Dec17	Jun18
Inventory-to-Revenue	Get a 7-Day Free Trial															0.88	0.33	0.26	0.18	0.22

Competitive Comparison of Sinclair Pharma's Inventory-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Sinclair Pharma's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinclair Pharma's Inventory-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sinclair Pharma's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sinclair Pharma's Inventory-to-Revenue falls into.

Sinclair Pharma Inventory-to-Revenue Calculation

Sinclair Pharma's Inventory-to-Revenue for the fiscal year that ended in Dec. 2017 is calculated as

	Inventory-to-Revenue (A: Dec. 2017 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Jun. 2015 )	+	Total Inventories (A: Dec. 2017 ))	/	count )	/	Revenue (A: Dec. 2017 )
=	( (10.58	+	4.832)	/	2 )	/	51.312
=	7.706					/	51.312
=	0.15

Sinclair Pharma's Inventory-to-Revenue for the quarter that ended in Jun. 2018 is calculated as

	Inventory-to-Revenue (Q: Jun. 2018 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Dec. 2017 )	+	Total Inventories (Q: Jun. 2018 ))	/	count )	/	Revenue (Q: Jun. 2018 )
=	( (4.832	+	5.97)	/	2 )	/	24.196
=	5.401					/	24.196
=	0.22

Sinclair Pharma (XPAR:SPH) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Sinclair Pharma's Days Inventory for the six months ended in Jun. 2018 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jun. 2018 )	/	Cost of Goods Sold (Q: Jun. 2018 )	*	Days in Period
	=	5.401	/	7.34	*	365 / 2
	=	134.29

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Sinclair Pharma's Inventory Turnover for the quarter that ended in Jun. 2018 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jun. 2018 )	/	Average Total Inventories (Q: Jun. 2018 )
	=	7.34	/	5.401
	=	1.36

Sinclair Pharma Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sinclair Pharma's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinclair Pharma (XPAR:SPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sinclair Pharma PLC (XPAR:SPH) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.sinclairispharma.com

Sinclair Pharma PLC is a United Kingdom-based specialty pharmaceutical company focused on Dermatology, in particular, Aesthetics, Wound care, and Skin care. The group has a direct sales and marketing presence in the top five European markets and a rapidly growing International division concentrated on key emerging markets through long-term multi-product, multi-country, sales & marketing and distribution deals with key strategic partners. The Company's reportable operating segments are International Operations, France, Italy, Germany, UK, and Spain.